21 November 2017
News and Views
Links and Services
This week's issue of the New England Journal of Medicine reports that sunitinib malate improves survival and reponse rate in patients with pancreatic neuroendocrine tumors.
The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuro
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors